LA-GLOBAL
LA-GLOBAL is a brand new conference from CELT Global Health on Thursday 29 - Friday 30 October 2026, at The Spine in Liverpool UK. It will spotlight progress and innovation, and foster partner commitments for the year ahead, incorporating enlightening presentations, keynote speakers, panels and networking.
About LA-GLOBAL
Long-acting therapeutics are transforming how we prevent and treat HIV, malaria, tuberculosis, hepatitis C virus, and a growing number of co-infections and comorbidities. But scientific innovation alone is not enough. Turning breakthrough research into real-world health impact - equitably, and for the people who need it most - demands a global, coordinated response.
LA-GLOBAL (the Long-Acting Gathering for Learning, Opportunity, Breakthroughs, Access and Leadership) exists to make that happen. Bringing together researchers, policymakers, funders, clinicians, and advocates from across the world, LA-GLOBAL is the meeting place where evidence, policy, and market action converge.
Our mission is clear: to accelerate the translation of long-acting science into equitable health outcomes, particularly for communities in low- and middle-income countries (LMICs) where the need is greatest and access has historically lagged furthest behind.
LA-GLOBAL Objectives
Through a programme combining plenary discussions, technical tracks, implementation showcases and policy dialogues, LA-GLOBAL's objectives are to:
- Advance knowledge and understanding in the science and technology of long-acting therapeutics through open scientific exchange
- Promote global health equity by prioritising meaningful LMIC participation and facilitating access to advances in long-acting therapeutics for the populations most in need
- Foster interdisciplinary collaboration across the long-acting pipeline, encompassing formulation and materials science, pharmacokinetics and pharmacodynamics (PK/PD), clinical implementation, modelling, biologics, manufacturing, paediatric and maternal health
- Support and develop early- and mid-career researchers (ECRs) through dedicated opportunities for presentation, recognition, and mentorship
- Facilitate a sustainable series of annual conference event through ongoing engagement with key stakeholders, CELT Global Health partners and Sponsorships partner commitments and coordinate a forward agenda that translates conference insights into tangible health and policy actions
- Disseminate outputs, including reports, white papers, thought pieces, peer-reviewed publications, and lay-accessible public-facing content, arising from the Conference.
LA-GLOBAL will incorporate enlightening presentations, keynote speakers and panels that will be aimed at highlighting progress, spotlighting innovation and foster partner commitments for the year ahead. The event will be aimed at prioritising attendance of participants from low- and middle-income countries.
Register
Tickets are available on our LA-GLOBAL registration page on the University of Liverpool online shop.
-591x394.jpg)
Abstract submission
Our abstract submission window is open until 23:59 (BST), Tuesday 23 June 2026.
Please submit your abstract via the LA-GLOBAL abstract submission form.
Abstract Submission Requirements
Please follow the instructions below carefully to ensure your abstract is successfully submitted and reviewed.
1. Eligibility
- Submissions are open to researchers, clinicians, policymakers, and industry professionals
- Abstracts must present original work that has not been previously published or presented at another conference
- Abstracts should align with at least one of the five themes of the 2026 LA-GLOBAL, as highlighted below these abstract submission requirements.
2. Submission Deadline
- All abstracts must be submitted by 23rd June 2026 at 23:59 PM (BST).
3. Abstract Format
- Title: Maximum 250 words
- Authors: List all contributing authors and affiliations
- Word limit: Maximum 250 words (excluding title and authors)
- Email: Provide valid email
- Structure:
- Background
- Methods
- Results
- Conclusions
- If a figure/graphs need to be included, please email this as an attachment referencing the title of the abstract to: askcelt@liverpool.ac.uk
- Avoid references, figures, and tables.
4. Submission Process
- Complete all required fields in the online submission form
- Upload or paste your abstract into the designated text box
- Select the most relevant theme or track for your submission
- Indicate your preferred presentation format (e.g. oral or poster), if applicable.
5. Review and Notification
- All abstracts will undergo peer review
- Notifications of acceptance will be sent by 17/08/2026
- Accepted abstracts may be published in conference materials.
6. Amendments and Withdrawal
- After submission, changes cannot be guaranteed
- To withdraw an abstract, please contact askcelt@liverpool.ac.uk.
7. Presenter Requirements
- If chosen to speak at the conference, the presenting author will be provided a complimentary registration
- Presenters are responsible for their own travel and accommodation
- A limited number of travel scholarships are available for investigators from low- and middle- income countries, allocated on the basis of merit and need. Applicants for either speaking or poster presentations wishing to be considered for travel support should indicate this on the form when submitting their abstract.
Back to top
LA-GLOBAL themes
LA-GLOBAL's programme and agenda are organised around 5 themes.
Advances in long-acting manufacturing
Long-acting medicines come in many formats. Topics include: advances in the generation of long acting medicines, such as, but not limited to microarrays, in situ forming implants and injectable drug dispersions; new approaches to long-acting therapeutics and descriptions of translational programmes.
Frontiers in long‑acting drug delivery
Long‑acting drug delivery systems are reshaping therapeutic practice by sustaining exposure and maximising clinical outcomes across the body. This session highlights cutting‑edge advances in implants, injectables, and device‑based platforms designed for both systemic and localised delivery. We will explore long‑acting technologies across ocular, otic, nasal, pulmonary, dermal, brain, and bladder routes, showcasing innovations that enable prolonged release, enhanced targeting, and new treatment possibilities for diverse clinical needs.
Safety and immuno-compatibility
Long-acting therapeutics rely on complex materials delivery systems and formulations that interact closely with the immune system and host biology. This theme will examine how biocompatibility immune responses and particle-biomaterial interactions influence safety efficacy and durability and how these biological insights can be integrated with PBPK and other pharmacometrics models (such as ordinal models for clinical adverse drug reactions) and vice versa to predict and improve clinical performance.
Pre-clinical pharmacology and pharmacometrics
Focus on predictive animal models, in vitro–in vivo correlations, dose‑fractionation, and safety pharmacology for prolonged exposures. Topics include but are not limited to better in vitro systems, population PK/PD, PBPK, and model‑informed drug development to provide better prediction or interpretation of human performance, and using clinical data to evaluate the performance of preclinical models for PK and efficacy.
Maternal and paediatric health
Long‑acting therapies can improve adherence and outcomes for mothers and children. Topics include but are not limited to new age‑appropriate formulations, drug transfer across the placenta, infant exposure through lactation, maternal‑foetal pharmacokinetics, with consideration of dosing flexibility and administration acceptability.
.jpg&fit=contain&w=720&h=480&trim=10)
.jpg&fit=contain&w=720&h=480&trim=10)
